Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Organogenesis Holdings ( (ORGO) ) is now available.
On August 5, 2025, Organogenesis Holdings Inc. amended its Credit Agreement to adjust financial covenants and accommodate its fiscal needs. The company reported a decrease in net product revenue to $100.8 million for the second quarter of 2025, compared to $130.2 million in the same period of 2024, with a net loss of $9.4 million, indicating a challenging financial period.
The most recent analyst rating on (ORGO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.
Spark’s Take on ORGO Stock
According to Spark, TipRanks’ AI Analyst, ORGO is a Neutral.
The overall stock score of 57.8 reflects significant financial challenges with declining revenue and profitability. However, strong technical momentum and strategic initiatives outlined in the earnings call provide a basis for cautious optimism. Poor valuation metrics underscore the need for careful consideration.
To see Spark’s full report on ORGO stock, click here.
More about Organogenesis Holdings
Organogenesis Holdings Inc. is a leading regenerative medicine company that develops, manufactures, and commercializes product solutions primarily for the Advanced Wound Care and Surgical & Sports Medicine markets.
Average Trading Volume: 1,147,848
Technical Sentiment Signal: Buy
Current Market Cap: $574.6M
For an in-depth examination of ORGO stock, go to TipRanks’ Overview page.